17h
Zacks.com on MSNNovavax (NVAX) Soars 11.4%: Is Further Upside Left in the Stock?Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
We recently published a list of 10 Unstoppable Stocks That Could Double Your Money. In this article, we are going to take a ...
7d
Zacks Investment Research on MSNNovavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on ItNovavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...
Shares of Novavax, Inc. (NASDAQ:NVAX – Get Free Report) have received an average recommendation of “Hold” from the seven ...
The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...
The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...
The FDA delays full approval for Novavax's COVID-19 vaccine, citing the need for additional data. Read more here.
Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.
Bullish option flow detected in Novavax (NVAX) with 12,673 calls trading, 2x expected, and implied vol increasing almost 14 points to 90.76%.
Novavax (NVAX) issued the following update on the FDA BLA for the company’s COVID-19 vaccine: “Novavax can confirm that April 1, 2025, was the ...
Novavax, Inc. (Nasdaq: NVAX) today announced that James Young, PhD, is retiring as Chair of the Board and Margaret McGlynn, RPh, has been appointed as his successor. The Company also appointed ...
Shares of Novavax Inc. NVAX slid 6.35% to $5.60 Thursday, on what proved to be an all-around dismal trading session for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results